Articles published by Evolus
![](https://mms.businesswire.com/media/20240809452447/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240731391926/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240731501783/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus to Hold Investor Day on September 12, 2024
July 31, 2024
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20240730687924/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240717426159/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240701537744/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240624339161/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240612853482/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
June 12, 2024
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20240607153632/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240520622093/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240515169929/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240510826268/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240507947366/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240423569346/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240417717464/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240412015960/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240326735225/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240311488324/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240308906332/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240307539329/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20240301797950/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240227499486/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20240222990989/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20240209938370/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20240116499593/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240112200734/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20240104945282/en/1788236/22/LOGO_NEW_SMALL.jpg)
![](https://mms.businesswire.com/media/20231219269963/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20231208831612/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From Evolus
Via Business Wire
Tickers
EOLS
![](https://mms.businesswire.com/media/20231110714369/en/1788236/22/LOGO_NEW_SMALL.jpg)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From Evolus
Via Business Wire
Tickers
EOLS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.